Elevance Health, Inc. (ELV) Reaffirms Full-Year 2025 Earnings Guidance

Elevance Health, Inc. (NYSE:ELV) is one of the 11 Best Roth IRA Stocks to Invest in Now.

Elevance Health, Inc. (NYSE:ELV) announced on September 4, 2025, that it expects to reaffirm its full-year 2025 earnings guidance during upcoming investor meetings. The company expects earnings of roughly $24.10 per diluted share, including roughly $5.90 per share in net unfavorable items. Excluding these, adjusted earnings of roughly $30.00 per diluted share are expected.

Furthermore, Elevance Health, Inc. (NYSE:ELV) also expects to achieve a benefit expense ratio close to 90% for the year. The company bases its projections on the current views on market conditions, regulatory factors, and medical cost trends.

With its Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands, Elevance Health, Inc. (NYSE:ELV) provides health benefits, pharmacy, and healthcare services across the U.S. It is one of the Best Roth IRA Stocks.

While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 10 Must-Buy Canadian Stocks to Invest in.

Disclosure: None.